Using AAV-mediated shRNA and the clinically applicable GalNAc-siRNA technology, the specific knockdown of hepatic Alkbh5 reversed hyperglycemia, hyperlipidemia, and the MAFLD phenotype in the db/db mouse model. This evidence concerns the gene ALKBH5 and Hyperglycemia.